Shares of Gland Pharma slumped as much as 11% to hit a 52-week low at ₹1,681. The development comes days after reports emerged that the pharmaceutical major’s parent company, Fosun International, is under financial distress. Moreover, last week, Gland Pharma reported weak earnings for the July-September quarter.
Over the past three…